Skip to main content

Diffuse Cutaneous Systemic Sclerosis clinical trials at UCSD
1 research study open to new patients

  • Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

    open to eligible people ages 18 years and up

    This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites in North America, Europe, Australia, and Asia. The planned duration of treatment with study drug is 52 weeks.

    La Jolla, California and other locations

Last updated: